Zymeworks (ZYME) Common Equity (2021 - 2026)

Zymeworks has reported Common Equity for 6 years, with the latest figure at $163.6 million in Q1 2026.

• Quarterly Common Equity fell 49.66% year-over-year to $163.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.6 million (down 49.66% YoY) and the FY2025 annual result came in at $268.5 million, down 20.74% from the prior year.
• Common Equity eased to $163.6 million in Q1 2026 per ZYME's latest filing, from $268.5 million in the prior quarter.
• Over five years, Common Equity peaked at $493.0 million in Q4 2022 and troughed at $163.6 million in Q1 2026.
• A 5-year average of $350.0 million and a median of $338.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2026: Common Equity jumped 136.06% in 2023, then tumbled 49.66% in 2026.
• Over 5 years, Common Equity stood at $493.0 million in 2022, then dropped by 5.71% to $464.8 million in 2023, then declined by 27.12% to $338.8 million in 2024, then dropped by 20.74% to $268.5 million in 2025, then sank by 39.07% to $163.6 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $163.6 million, $268.5 million, and $320.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.